Role of Copper and Cholesterol association in the neurodegenerative process by Arnal, Nathalie et al.
Hindawi Publishing Corporation
International Journal of Alzheimer’s Disease
Volume 2013, Article ID 414817, 15 pages
http://dx.doi.org/10.1155/2013/414817
Research Article
Role of Copper and Cholesterol Association in
the Neurodegenerative Process
Nathalie Arnal,1 Gustavo R. Morel,1 María J. T. de Alaniz,1
Omar Castillo,2 and Carlos A. Marra1
1 INIBIOLP (Instituto de Investigaciones Bioquı´micas de La Plata), CCT La Plata, CONICET-UNLP, Ca´tedra de Bioquı´mica y
Biologı´a Molecular, Facultad de Ciencias Me´dicas, Universidad Nacional de La Plata, 60 y 120 (1900) La Plata, Argentina
2 CIC (Centro de Investigaciones Cardiovasculares), CCT La Plata, CONICET-UNLP, Facultad de Ciencias Me´dicas,
Universidad Nacional de La Plata, 60 y 120 (1900) La Plata, Argentina
Correspondence should be addressed to Carlos A. Marra; contactocarlos@hotmail.com
Received 7 July 2013; Revised 5 September 2013; Accepted 5 September 2013
Academic Editor: Rosanna Squitti
Copyright © 2013 Nathalie Arnal et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Age is one of the main factors involved in the development of neurological illnesses, in particular, Alzheimer, and it is widely held
that the rapid aging of theworld population is accompanied by a rise in the prevalence and incidence ofAlzheimer disease.However,
evidence from recent decades indicates that Cu andCho overload are emerging causative factors in neurodegeneration, a hypothesis
that has been partially investigated in experimental models. The link between these two variables and the onset of Alzheimer
disease has opened up interesting new possibilities requiring more in-depth analysis. The aim of the present study was therefore to
investigate the effect of the association of Cu +Cho (CuCho) as a possible synergistic factor in the development of anAlzheimer-like
pathology inWistar rats.Wemeasured total- and nonceruloplasmin-bound Cu and Cho (free and sterified) contents in plasma and
brain zones (cortex and hippocampus), markers of oxidative stress damage, inflammation, and programmed cell death (caspase-3
and calpain isoforms). The ratio beta-amyloid (1-42)/(1-40) was determined in plasma and brain as neurodegenerative biomarker.
An evaluation of visuospatial memory (Barnes maze test) was also performed. The results demonstrate the establishment of a
prooxidative and proinflammatory environment after CuCho treatment, hallmarked by increased TBARS, protein carbonyls, and
nitrite plus nitrate levels in plasma and brain zones (cortex and hippocampus) with a consequent increase in the activity of calpains
and no significant changes in caspase-3. A simultaneous increase in the plasma A𝛽1-42/A𝛽1-40 ratio was found. Furthermore, a
slight but noticeable change in visuospatial memory was observed in rats treated with CuCho. We conclude that our model could
reflect an initial stage of neurodegeneration in which Cu and Cho interact with one another to exacerbate neurological damage.
1. Introduction
The aging of the world population is being accompanied by
a rise in the prevalence and incidence of Alzheimer disease
(AD) and other neurodegenerative illnesses. In the USA, the
number of patients with AD is expected to increase to 13
million by 2050 and in the European Union (EU) to over 4
million [1]. The mortality rate of AD is second only to cancer
and stroke. Epidemiologic data indicates that the world
population will have grown considerably by 2025 and the
percentage of elderly people will be significantly higher [2].
Since age is one of the major risk factors in the development
of AD, it is expected that the incidence of this disease will
also increase. However, experimental evidence detailed in a
review by Brewer indicates that other factors in addition to
age could play a critical role [3] in the development of diseases
such as Alzheimer and that the contribution of inorganic
copper (Cu) has been underestimated. It is widely known
that more than 95% of AD cases are sporadic and only 2–
7% are genetically determined [4]. Thus, any environmental
factors likely to have an etiopathogenic role in AD should be
investigated.
Though Cu is essential to human health, Cu overload
has been associated with mental decline [5] and particularly
with AD development [3, 6, 7]. Data from Squitti’s group
specifically demonstrated that free Cu (also known as NCBC
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or nonceruloplasmin-bound Cu) is elevated in the blood
of AD patients, negatively correlates with cognition, and
predicts the rate of loss of cognition [8–10].More recently, our
group corroborated these findings in an independent human
cohort and demonstrated that increased NCBC has a direct
impact on the disease duration [11]. We also proposed the
NCBC/ceruloplasmin ratio as a predictive marker of risk for
the first-degree relatives of AD patients. Sparks and Schreurs
[12] first demonstrated that Cu supplementation in drinking
water given to rabbits under a diet with excess cholesterol
(Cho) produced an induction of 𝛽-amyloid plaques and a
learning deficit. In addition, Lu et al. reported that trace
amounts of Cu activate the apoptotic cascade and exacer-
bate beta amyloid-induced neurotoxicity in Cho-fed mice
through a TNF-mediated inflammatory pathway [13, 14].
Very recently, Brewer has reviewed the theory of inorganicCu
toxicity in Alzheimer disease as a causative factor in cognitive
loss [6]. However, the question of how inorganic Cu might
trigger a neurodegenerative process is still a matter of debate
[15].
The degree of exposure of human populations to Cu is
also a controversial issue. There is little data on Cu overload
in humans sincemost of the available evidence (experimental
or epidemiological) was obtained from animal models. How-
ever, the regulatory framework for chronic Cu exposure in
large human populations indicates that pollution, drinking
water, and dietary Cu-containing supplements are the main
sources of exposure [6, 16]. The dietary reference intake for
people in the USA, United Kingdom, Europe, and Australia
varies from 0.16 to 0.98 (Estimated Average Requirements)
EAR or (Recommended Dietary Allowance) RDA expressed
in mg Cu/kg body weight, with considerable variations as a
function of age. The (Population Reference Intake) PRI was
reported between 0.3 and 1.5mg Cu/kg body weight [16];
however, these limits were largely surpassed in many circum-
stances such as ingestion of fish, bivalves, or contaminated
drinking water [3, 17]. In accumulated data on 280 samples
of household drinking water all across North America, 72%
of the samples have Cu levels above those enhancing AD
in experimental models [3]. The content of inorganic Cu
in dietary supplements can be as high as 3mg/pill (approx.
2mg above the EAR or RDA). Furthermore, we and others
have demonstrated significantly higher Cu levels in plasma
of women using Cu-IUDs and in blood samples from farmers
working with Cu-based pesticides [17–19]. Most importantly,
we found alterations in Cu homeostatic biomarkers in neu-
rodegenerative patients and their first-degrees relatives [11].
Fat ingestion has also been linked to AD prevalence [20].
Specifically, Cho has been associated with oxidative stress
and AD development [21, 22], with most of the experimental
evidence emerging from exploration of the role of Cho in 𝛽-
amyloid formation [23]. Despite the paucity of epidemiolog-
ical data from human studies, it is reasonable to assume that
Cho plays at least some role in learning and memory and is
associated with AD pathogenesis [24]. Of particular interest
is evidence showing that Cu greatly exacerbates cognitive
decline in those people included in the highest quintile
of fat ingestion [25]. Experimental evidence obtained from
rabbit and mouse models suggests that the association of
Cu and Cho can be risk factor for AD development [12–14].
Moreover, it was hypothesized that Cu could oxidize Cho,
generating substances toxic to the brain [3].
However, the mechanism of action of Cu and Cho in
AD incidence and development is poorly understood and
requires further investigation.Thus, the aim of this work was
to study the effects of Cu andCho association on the twomain
brain areas affected in AD, cortex and hippocampus, using
a model of Wistar rats. Specifically, we aimed to determine
for each nutritional supplement alone or in combination (i)
the capacity to install oxidative/nitrative damage; (ii) changes
in the levels of the main antioxidant molecules (glutathione
and 𝛼-tocopherol); (iii) the possible development of a pro-
inflammatory condition by analyzing the concentration of
prostaglandins PGE2 and PGF2𝛼; (iv) the activities of the
two main protease systems associated with programmed cell
death, caspase-3 and calpains (𝜇- and m-); and (v) possible
changes in visuospatial memory as assessed by means of the
Barnes maze test.
Our findings could be useful in further investigating the
mechanisms underlying the neurodegenerative process and
also in localizing putative targets for preventive interventions
associated with endogenous and/or exogenous causative
factors such as Cu and Cho, alone or in combination.
2. Material and Methods
2.1. Chemicals. All chemicals used were of analytical grade
and obtained from Sigma Chem. Co. (Buenos Aires, Arge-
ntina orUSA),Merck (Darmstadt, Germany), andCarlo Erba
(Milan, Italy).
2.2. Animals and Treatments. Certified pathogen-free male
Wistar rats were used. The rats were maintained at a con-
trolled temperature (25∘C) and relative humidity of 60%
with forced ventilation, under a normal photoperiod of
12 h darkness and 12 h light. The health of the animals was
monitored in accordance with the internationally recom-
mended practices of the (Institute of Laboratory Animal Reso-
urces, Commission of Life Sciences, National Research Council)
ILAR. Solid food and drinking water were provided ad
libitum. The diets for the experiments were prepared in our
laboratory according to the recommendations for Wistar
rats [26]. All procedures for handling the animals followed
the NIH regulations [27]. The experimental protocol was
reviewed and approved by (Bioethics Committee of the
Faculty of Medical Sciences, UNLP) COBIMED under the
code # 00382/11.
2.3. Experimental Protocols. Rats (21 days old)were randomly
assigned (ten animals per group) to the protocols detailed as
follows and treated during eight weeks.The control group (C)
was maintained on lab-prepared pellets as recommended for
normal growth, containing 7 ppm of Cu [28, 29]. The Cu-
supplemented experimental group (Cu) was fed on control
pellets and tap water supplemented with 3mg/L (or ppm) of
Cu in the form of ultrapure CuSO
4
(Merck, Darmstadt, Ger-
many), theCho-supplemented group (Cho)was fed onpellets
containing 2% (W/W) of Cho (87% pure) (obtained from
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Saporiti SRL, Buenos Aires, Argentina), and the Cu + Cho-
supplemented group (CuCho) was simultaneously treated
with Cu in water + Cho in food. Rats were monitored
during the experimental period to observe their behavior,
quantify water, and food consumption and determine their
body weight gain. Total Cu concentration in tap water sup-
plemented with CuSO
4
was determined by means of atomic
absorption methodology and was 3.42 ± 0.21 ppm (means
of all daily measurements along the experimental period).
Considering that each animal imbibed between 4.9 ± 0.4 and
15.0 ± 1.1mL water/day (at the beginning and the end of the
protocol, resp.), a maximum of 0.01 to 0.05mg Cu/day was
acquired from water (a dose equivalent to 0.06 and 0.18mg
Cu/Kg live animal, resp.). Linear regression curves and
ANOVA test for Cu content in food demonstrated that there
were no significant variations between the 6 preparations
used for the experiments (7.22 ± 0.31 ppm or mg Cu/Kg
diet). Fe and Zn content (determined by atomic absorption
spectrometry) were the same in all preparations (45.9 ± 1.8
and 66.6 ± 2.0 ppm, resp.). Ingestion of solid food along the
experiments varied from 11.6±0.8 to 29.7±2.8 g/rat, implying
that the oral ingestion ofCuwas in the range of 0.08 to 0.21mg
Cu/day/rat (0.90 to 1.21mg Cu/Kg live animal, a mean of
1.06 ± 0.11mg Cu/Kg).
2.4. Sample Collection. At the end of the treatments, ani-
mals were deeply anesthetized with ketamine (70mg/Kg)
and xylazine (5mg/Kg) applied intramuscularly and then
sacrificed by decapitation. Brains were rapidly taken out
and dissected in two zones, cortex and hippocampus, using
the atlas of Paxinos and Watson [30] as a guide for tissue
dissection and a Binocular Stereoscopic Arcano Ztx-1065
Microscope (Instrumental Pasteur, BuenosAires, Argentina).
Both brain regions were washed, weighed, and homoge-
nized using a buffer Tris/HCl (10mM pH 7.4) with sucrose
(70mM), mannitol (230mM), ethylenediaminetetraacetic
acid (EDTA) (1mM), and dithiothreitol (DTT) (1mM).
2.5. Atomic Absorption Measurements. Aliquots of sample
were digested with a mixture of 4mL of HNO
3
(c) and
1mL HClO
4
(Aldrich or Sigma Chem. Co., Buenos Aires,
Argentina) by heating at 120∘C for 80min in a mineralization
block [31]. The digests were cooled, diluted with ultrapure
water (18mΩ cm, Carlo Erba, Milan, Italy), and ultrafiltered
by a 0.22𝜇m Millipore membrane (Milli-Q Purification
System, fromMillipore, CA, USA). Ultrafiltered dissolutions
were directly aspirated into the flame of a Perkin-Elmer
1100 B Spectrophotometer equipped with a Perkin-Elmer
cathode lamp (Perkin-Elmer Corp., Norwalk, CT, USA) at a
spectral width of 1 nm. Standard solutions of 100 ppm from
HCR Inc. (QuimiNet, Buenos Aires, Argentina) were used
for Zn and Fe. Cu determinations were calibrated with a
standard solution (200 ppm) of Cu (NO
3
)
2
in HNO
3
0.5N
(Tritrisol from Merck Co., Darmstadt, Germany). All mea-
surements were carried out in peak height mode (324.7 nm
line). The intra-[(SD/x)⋅100] and inter-[(ΔSD/Δx)⋅100] assay
coefficients of variation were 15.5 and 6.0%, respectively. We
routinely obtained a similar equation for the calibration curve
(IR = 55.10−5 + 0.048⋅[Cu, mg/L]), and the statistical analyses
demonstrated a correlation coefficient always between 0.95
and 0.99. In addition, we explored the so-called matrix
effects that could have modified the slopes of the standard
regressions. In spiked samples the obtained values varying
from 48 to 60.10−5 were very similar to those of Cu standard
solutions, indicating that the matrix effect was not significant
or was negligible. The mean for recovery and RSD for
spiked samples was 99.7% and 3.3%, respectively, and the
detection limit was 0.09mg/L. In order to verify the accuracy
of the method, we explored the influence of time after
dilution, temperature of acid digestion, and concentration
of HNO
3
/HClO
4
following the suggestions of Terre´s-Martos
et al. [32]. We also checked our results with biological
samples (plasma and homogenates) against a SeronormTrace
Elements Serum (from Sero Labs, Billingstad, Norway) and
found no significant differences between the obtained and the
declared (certified) concentrations.
2.6. Ceruloplasmin (CRP) Levels and Nonceruloplasmin-
Bound Copper (NCBC). Samples were analyzed by the enz-
yme conversion of p-phenylenediamine into a blue-colored
product [33] which was then measured at 550 nm. Reaction
proceeded at 37∘C in buffer glacial acetic/sodium acetate
(50mM, pH 5.5) directly into flat-bottomed plates, using a
Microplate Reader SpectraMax M2/m2𝑒 model from Molec-
ular Devices Analytical Technologies (Sunnyvale, CA, USA)
for 3min. Intra- and interassay coefficients of variation
were 8.3 and 4.4%, respectively. CRP concentrations were
calculated by comparison with the reaction rate of pure CRP
standard (Sigma Chem. Co., Buenos Aires, Argentina). Using
the Cu and CRP data, we calculated the non-CRP-bound Cu
(NCBC, or so-called free Cu) as described by Brewer [3] by
subtracting the amount of Cu bound to each mg of CRP
from data of total Cu. This parameter can be easily expressed
in percentages using the formula (([Cu]-47.2 × [CRP]) ×
100/[Cu]), where Cu is in 𝜇mol/L and CRP is in g/L [34].
2.7. Lipid Analysis. Total lipids were extracted by the method
of Folch et al. [35]. Aliquots of this solution were taken to
measure total Cho by an enzymatic method using a comme-
rcial kit fromWienner Lab (Rosario, Argentina). To estimate
the amount of esterified Cho (ECho), aliquots of the lipid
extracts were seeded in high-resolution pre-coated silica
gel plates (10 × 20 cm) with a concentration zone for thin
layer chromatography (Whatman Adsorption 60 A˚ Silica
Gel HP-TLC Plates, CA, USA) and developed with diethyl
ether : hexane : acetic acid (90 : 4 : 1, by vol) as described
elsewhere [36]. Authentic standards of Cho and Cho-esthers
(from Avanti Polar Lipids, Ontario, Canada) were run in
parallel and revealed by iodine vapors. Identified zones were
scraped off the plates, eluted with Folch reactive, evaporated,
dissolved in 50mM phosphate buffer (pH 7.4) with 1%
sodium deoxycholate, and enzymatically analyzed using the
commercial kits fromWienner Lab (Rosario, Argentina).
2.8. Biomarkers of ROS Production. Thiobarbituric acid-
reactive substances (TBARS) were measured in brain homo-
genates as previously described [37]. TBARS (mainly malon-
dialdehyde, MDA) reacted with 2-thiobarbituric acid (TBA)
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to yield TBA-MDA adducts which were quantified at 532 nm.
The concentration of the chromophore was calculated from a
calibration curve prepared with fresh tetramethoxypropane
(TMP) solutions (TMP was purchased from Sigma Chem.
Co., Buenos Aires, Argentina). Nitrate and nitrite [NOx]
concentration were measured using the method of Griess
on samples previously reduced with vanadium chlorohydrate
according to Miranda et al. [38]. Quantification was per-
formed after calibration with standard solutions of sodium
nitrate from Merck Co. (Darmstadt, Germany). Protein
carbonyls (PCs) were determined by the method of Reznick
and Packer [39]. The concentrations of PCs were calculated
from a calibration curve prepared with a stock solution of
sodium pyruvate (Sigma Chem. Co.).
2.9. Antioxidant Defense System
2.9.1. Reduced (GSH) and Oxidized (GSSG) Glutathione Con-
tent. Total glutathione was determined by the glutathione
reductase/dithionitrobenzoic (DTNB) method that can mea-
sure both GSH and GSSG [40]. To calculate the GSH/GSSG
ratio, samples were reanalyzed after derivatization with
divinylpyridine (3mM final concentration).
2.9.2. Vitamin E (𝛼-tocopherol). Vitamin E (𝛼-tocopherol)
was measured after extraction with the Buttriss and Diplock
method [41] using the HPLC technique of Bagnati et al.
[42] in a reverse phase/C-18 silica column from ALLTECH
Associates, Inc. (Deerfield, IL, USA). The ECONOSIL C
18
column with a Direct-connect Cartridge Guard Column
System was operated at a maximum pressure of 500 psi in a
Hitachi HPLC System (Tokyo, Japan).The amount of vitamin
was electronically calculated using internal calibration with
pure 𝛼-tocopherol (Sigma, Bs. As.), and the results were
expressed in 𝜇M concentration of 𝛼-tocopherol.
2.9.3. Glutathione Reductase (GR). GR activity was deter-
mined by the method of Carlberg and Mannervik [43]. The
specific activity of the enzyme was calculated for each sample
in terms of U/min⋅mg protein (𝜀 = 6.22 nM−1⋅cm−1 for abso-
rbance at 340 nm).
2.10. Biomarkers of Inflammation. Prostaglandin F2𝛼 (PG
F2𝛼) and prostaglandin E2 (PGE2) were measured using the
PGF2𝛼 EIAKit and PGE2 Express EIAKit, respectively (Cay-
man, Migliore Laclaustra S.R). The results were expressed as
ng of each prostaglandin/mg total protein.
2.11. Programmed Cell Death Biomarkers
2.11.1. Caspase-3Activity. Caspase-3 activitywasmeasured by
a colorimetric assay kit (CASP-3-C) based on the hydrolysis
of the synthetic peptide substrate acetyl-Asp-Glu-Val-Asp-p-
nitroaniline (Ac-DEVD-pNA) by caspase-3 (Sigma Chem.
Co., Buenos Aires, Argentina). The resulting p-nitroaniline
(p-NA) was monitored at 405 nm. Each assay was run in
parallel with inhibitor-treated homogenates (to measure the
nonspecific hydrolysis of the substrate) and caspase-3 positive
control (using commercial caspase-3, 5mg/mL provided by
the kit manufacturer). A calibration curve using a standard
solution of p-nitroaniline (p-NA) was also run for each assay
to calculate the activity of the protease expressed as 𝜇mol p-
NA released/min⋅mg protein.
2.11.2. Milli- (m-) and Micro- (𝜇-) Calpains. The assay
involves the hydrolysis of whole ultrapure casein (Sigma,
Chem. Co., CA, USA) by calpain activity and the subsequent
detection of trichloroacetic acid (TCA) soluble peptidic
fragments at 280 nm [44]. To select the activity of the calpain
isoforms, the level of calcium in the medium was regulated
(5mM or 500𝜇M of CaCl
2
for m- or 𝜇-calpain, resp.). The
activity of calpains was calculated considering that a unit
of calpain is the amount of enzyme that produces a change
of absorbance of 0.01 at 280 nm. Results were expressed as
units/min⋅mg of protein.
2.12. Markers of Neurodegeneration
2.12.1. Beta Amyloid Peptides (1-40) and (1-42). Beta amy-
loid peptides (A𝛽) (1-40) and (1-42) were measured using
Human/Rat𝛽Amyloid-40 ELISAkitWako II and theHuman
Amyloid-42 ELISA kit Wako High-Sensitivity, respectively.
The A𝛽(1-42)/(1-40) ratio was then calculated from the
individual data expressed as picomole of the respective A𝛽
peptide/mg total protein.
2.12.2. Barnes Maze Test. The Barnes maze is a black acrylic
circular platform, 122 cm in diameter and elevated 108 cm
off the floor, containing twenty holes around the periphery.
The 10 cm diameter holes are uniform in appearance but, one
hole is connected to an escape box, consisting of a 38.7 cm
long × 12.1 cm wide × 14.2 depth cm removable box. Four
proximal visual cues (30 cm high, opaque black geometric
figures: a cross, a circle, a square, and a triangle) were located
in the room 50 cm from the circular platform. The escape
box remained in a fixed position relative to the cues, to
ensure randomization of the hole associated with the escape
tunnel. In the center of the platform is a starting chamber (an
opaque, 26 cm diameter, 20 cm high, and white plastic open-
ended cylinder). A 90 dB white-noise generator and a white-
light 500W bulb provided motivation for escaping from the
platform. The acquisition session and the probe trial session
were performed on the same day. In brief, the experiment
consisted of eight acquisition trials (t1–t8) followed by a single
evaluation trial (t9). Acquisition trials began with the animal
inside the starting chamber for 30 seconds in the presence of
a constant buzz. The chamber was then raised, the aversive
stimulus (intense bright light) was switched on, and the rat
was allowed to freely explore the maze. The rats were each
given 120 s to locate the correct hole. If by the end of this
period they had not entered the escape box of their own
accord, they were gently picked up and placed over the hole
above the escape box. The evaluation trial proceeded in the
same manner as described above but without the start box.
At the end of each trial, the aversive stimulus was switched
off, the rat remained on the escape box during 60 s, and
the white light was switched off. In order to eliminate any
possible olfactory clues from the maze, it was cleaned with
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Table 1: Copper (Cu) levels in animals fed with the experimental diets.
Diets
Cu (ng/mg prot)
Plasma Brain
Total NCBC Cortex Hippocampus
Total NCBC Total NCBC
Control 18.5 ± 0.8a 0.95 ± 0.11a 5.5 ± 0.2a 0.25 ± 0.04a 4.8 ± 0.1a 0.27 ± 0.04a
Cu 23.2 ± 0.7b 1.76 ± 0.15b 7.1 ± 0.1b 0.27 ± 0.02a 6.1 ± 0.1b 0.33 ± 0.02b
Cho 18.1 ± 1.0a 0.91 ± 0.05a 5.4 ± 0.2a 0.24 ± 0.04a 5.1 ± 0.2a 0.25 ± 0.04a
CuCho 22.9 ± 0.6b 1.78 ± 0.10b 7.0 ± 0.1b 0.29 ± 0.03a 6.2 ± 0.04b 0.35 ± 0.03b
Cu content was determined after mineral digestion of the samples by atomic absorption spectrometry as described in Section 2.5. Results are the mean of 10
independent measurements analyzed in triplicate ± SD. Comparisons between data were performed by ANOVA + Tukey test at𝑃 < 0.01. Statistical differences
among the experimental diets were indicated with distinct superscript letters (values within the same column with different superscript letters are statistically
significant between them).
Table 2: Esterfied (ECho) and free (FCho) cholesterol levels in animals fed with the experimental diets.
Diets
Cho (nmoles/mg⋅prot)
Plasma Brain zones
Cortex Hippocampus
Esterified Free FCho/Echo Esterified Free FCho/Echo Esterified Free FCho/Echo
C 16.4 ± 0.3a 10.6 ± 0.2a 0.64 ± 0.05a 28.2 ± 1.9a 257.8±10.6a 9.14 ± 0.71a 28.7 ± 2.2a 247.1 ± 9.7a 8.61 ± 0.60a
Cu 16.8 ± 0.4a 11.7 ± 0.3a 0.70 ± 0.05a 35.8 ± 2.2b 260.2 ± 7.3a 7.26 ± 0.42b 39.2 ± 1.8b 252.1 ± 11.4a 6.43 ± 0.33b
Cho 22.2 ± 0.4b 11.5 ± 0.4a 0.51 ± 0.03c 30.6 ± 2.1a 281.3±12.2b 9.19 ± 0.55a 28.0 ± 1.7a 269.4 ± 11.4b 9.62 ± 0.21c
CuCho 18.3 ± 0.5a 15.5 ± 0.5c 0.85 ± 0.05d 70.0 ± 3.1c 225.3±15.0c 3.21 ± 0.13c 77.5 ± 2.7c 233.6±11.5a 3.01 ± 0.11d
Cho and Cho-esters contents were determined enzymatically after HP-TLC as described in Section 2.7. Results are the mean of 10 independent measurements
analyzed in triplicate ± SD. Comparisons between data were performed by ANOVA + Tukey test at 𝑃 < 0.01. Statistical differences among the experimental
diets were indicated with distinct superscript letters (values within the same columnwith different superscript letters are statistically significant between them).
10% ethyl alcohol solution at the beginning of the 15min
intertrial period. An individual hole exploration was defined
as being a single downward head deflection toward the inside
of the hole. The following parameters were determined: (i)
first-hole latency time (in s) spent by the animal between
being released from the start box and exploring a hole in the
maze for the first time; (ii) escape-box latency time (defined
in the acquisition and retention test trials as the time (in s)
spent by the animal between being released from the start
box and entering the escape box and, in the case of the
preference test and extinction trials, the time elapsed before
the first exploration of the escape hole); and (iii) nongoal hole
exploration (defined as the number of explorations of holes
other than the escape hole, the explorations being considered
as errors during the acquisition and probe trials). In the case
of the evaluation trials, we evaluated the hole exploration
frequency (the number of explorations of each hole during
the trial in which the escape hole was numbered as hole
0 for normalized graphical representation purposes, 1 to 10
clockwise, and −1 to −9 counterclockwise). The behavioral
measurements were recorded using a video camera mounted
110 cm above the platform, linked to a computer. The video
performances of each rat were analyzed using the video
analysis software Kinovea-Creative Commons Attribution (v
0.7.6).
2.13. Statistical Analysis. All values represent the mean of
6 rats assayed in triplicate expressed as mean ± standard
deviation (SD). Data were analyzed by ANOVA plus Tukey
test with the aid of SPSS 11.0.1 software (SPSS Inc., Chicago,
IL). To analyze the data from the Barnes maze test, multiple
comparisons were drawn with the control group using two-
way ANOVA plus the Holm-Sidak post hoc test at two levels
of significance (𝑃 < 0.05 and 0.01). Data were also analyzed
using MANOVA with identical final conclusions. Results
were also plotted and analyzed using Sigma Scientific Graph-
ing Software (version 11.0) from Sigma Chem. Co. (St. Louis,
MO). The statistical significance of differences is indicated
by distinct superscript letters (data with distinct superscript
letters are statistically different (𝑃 < 0.01) between them).
3. Results
3.1. Cholesterol and Copper Levels. Table 1 shows the levels
of total and free Cu (NCBC or nonceruloplasmin-bound
Cu) in plasma and in brain cortex and hippocampus after
the experimental treatments. Plasma total Cu and NCBC
exhibited discrete (but statistically significant) increases in
those groups receiving Cu (Cu and CuCho). Total Cu also
increased in both cortex and hippocampus after Cu supple-
mentation (alone or in combination with Cho). Cortex shows
a nonsignificant tendency towards higher NCBC after Cu or
CuCho treatments, whereas hippocampus shows a significant
increase in this parameter with respect to the control group.
The results of the Cho analysis (free and esterified) are
shown in Table 2, from which it is evident that tissue from
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Figure 1: Oxidative/nitrative stress biomarkers in plasma (a) and brain cortex and hippocampus (b). Lipid peroxidation (TBARS) (nmol
MDA/mg protein), protein oxidation (PCs) (nmol MDA/mg protein), and concentration of nitrites and nitrates ([NOx]) (𝜇mol/mg protein)
were determined in plasma and brain cortex and hippocampus following the procedures described in described in Material and Methods
Section. Treatments are indicated with different colors. Control (white bars), Cu (gray bars), Cho (dark gray bars), and CuCho (black bars).
Results are expressed as mean of 10 rats assayed in triplicate ± standard deviation (SD). Significant differences were indicated by letters (data
with distinct letters are statistically different between them at 𝑃 < 0.01).
the central nervous system has a particular Cho metabolism
characterized by higher levels of free Cho (25 times higher
than in the case of plasma). Samples from brain and plasma
behave differently from one another. Cu addition to drink-
ing water produced no significant changes in plasma total
Cho and a slight increase in cortex and hippocampus at
the expense of the esterified form (ECho). Furthermore,
Cu did not change the ratio between free and ECho in
plasma samples but did lower this parameter in the brain
homogenates. Supplementing food with Cho caused a higher
level of total Cho in peripheral plasma (from 27.0 ± 0.5 in
the control group to 33.7 ± 0.6 nmoles/mg protein in Cho-
supplemented rats) with a slight but significant decrease in
the proportion of free/Echo. In brain, all the treatments led
to an increase in total (free + esterified) Cho with respect to
control data, though the increasewas substantially higher and
differentially orchestrated in those groups receiving Cho sup-
plementation. In the case of Cho-treated rats, this occurred
at the expense of free Cho; however, in rats under CuCho
treatment, it was at the expense of the ECho form. Under
CuCho treatment, hippocampus reached even higher values
of total Cho than cortex (approx. 311 versus 295 nmoles/mg
protein). Addition ofCu alone significantly elevated the ECho
in both brain tissues, more noticeably in hippocampus than
in cortex. Another differential result for the CuCho group
was a decrease in free Cho with respect to control rats in
cortex, a phenomenon not observed in hippocampus. The
results obtained for the ratios between free and ECho strongly
suggest that Cu addition was able to modify the balance of
these two parameters, triggering the accumulation of ECho in
cortex and hippocampus, perhaps facilitating its esterification
or impeding its degradation, or both. This effect is especially
noticeable under conditions of simultaneous Cu and Cho
overload and, even more interestingly, was contrary to the
effect observed in peripheral plasma samples.
3.2. Biomarkers ofOxidative Stress. In order to detectwhether
inorganic Cu in drinking water and Cho in food produced
oxidative/nitrative stress, we measured the oxidation end
products of lipids (TBARS) and proteins (PCs) and also
the levels of NOx (nitrates and nitrites derived from the
spontaneous dismutation of nitric oxide) as biomarkers of
damage. Levels of the three markers analyzed were higher
afterCuCho treatment both in plasma and in brain cortex and
hippocampus (Figures 1(a) and 1(b)). In plasma, treatment
with Cu alone increased TBARS levels (Figure 1(a)), whereas
all three biomarkers were significantly increased after CuCho
cosupplementation. Brain homogenates exhibited similar
results, with increased levels of all three biomarkers after Cu
or CuCho supplementation (with the solo exception of PCs in
both brain regions, which increased only with simultaneous
exposure to Cu and Cho).
We also measured the levels of the two main antiox-
idant molecules for water- and lipid-soluble cellular com-
partments (total glutathione-GSH+GSSG- and 𝛼-tocopherol,
resp.) (Table 3). Plasma levels of total glutathione were higher
in rats fed on Cu plus Cho supplements. In the same experi-
mental group (CuCho), the 𝛼-tocopherol concentration was
27% lower than in the control data. In brain cortex, we
also observed an increase in total glutathione after CuCho
treatments and a simultaneous increment in the GSSG/GSH
ratio as a consequence of a higher level of GSSG. Concomi-
tantly, the activity of glutathione reductase (GR) in cortexwas
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Figure 2: Prostaglandin PGF2𝛼 and PGE2 levels in brain cortex and
hippocampus homogenates (ng/mg total protein). Treatments are
indicated with different colors. Samples were analyzed as indicated
in Section 2.10. Control (white bars), Cu (gray bars), Cho (dark gray
bars), and CuCho (black bars). Results are expressed as mean of
10 rats assayed in triplicate ± standard deviation (SD). Significant
differences were indicated by letters (data with distinct letters are
statistically different between them at 𝑃 < 0.01).
enhanced byCu supplementation and evenmore so by simul-
taneous treatment with Cu + Cho. The level of 𝛼-tocopherol
(𝛼-Toc) decreased significantly only after CuCho treatment
(approx. 17% compared to control data). In hippocampus,
the behavior was very similar, with the exception of the
increment in total glutathion content. Thus, hippocampus
homogenates showed a significant increase in theGSSG/GSH
ratio, activation of GR in Cu- and CuCho-treated rats, and
a ca. 34% decrease in 𝛼-Toc content compared to control
data, with this latter being observed only in the CuCho
experimental group.
3.3. Markers of Inflammation. In order to evaluate whether
simultaneous supplementation with Cu and Cho also pro-
duced an inflammatory condition, we analyzed the levels
of two proinflammatory prostaglandins, PGE2 and PGF2𝛼
(Figure 2). In both brain regions, cosupplementation signif-
icantly increased prostaglandin levels. Interestingly, Cu and
Cho alone also increased prostaglandins levels with respect
to control data, and association of the two supplements
produced an additive effect.
3.4. Caspase-3 and Calpains Activities. We also explored
whether the prooxidative and proinflammatory environment
developed after CuCho treatment was able to trigger apop-
totic signals, to which end we determined the activities of
the two main protease systems involved in programmed cell
death, caspase-3, and calpains (𝜇- andm-). Caspase-3 activity
tends to increase at least in cortex homogenates, but not to a
statistically significant degree (Figure 3). Both calpain (milli-
and microisoforms) activities increased after Cu treatment
Ca
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ot
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CuCho
Figure 3: Caspase-3 (U/mg total protein) activity in brain cortex
and hippocampus homogenates. Samples were analyzed according
to the procedure described in Section 2.11.1. Treatments are indi-
cated with different colors. Control (white bars), Cu (gray bars),
Cho (dark gray bars), and CuCho (black bars). Results are expressed
as mean of 10 rats assayed in triplicate ± standard deviation (SD).
There are no statistically significant differences (𝑃 < 0.01) between
treatments.
and evenmore so after CuCho supplementation in both brain
zones (Figure 4).
3.5. Biomarkers of Neurodegeneration. The concentration of
the 𝛽-amyloid peptides (1-42 and 1-40) and the A𝛽 1-42/1-40
ratio in cortex and hippocampus are shown in Table 4. The
ratio (which is the main indicator of neurodegenerative pro-
cess) was different, depending on the brain zone examined. In
cortex, it was found to increase after Cu and Cho treatments
and to further increase after CuCho supplementation. In hip-
pocampus, the A𝛽 42/40 ratio increased only in the CuCho
experimental group. There were no statistically significant
changes of the ratio (1-42)/(1-40) in peripheral plasma.
We also investigated possible alterations in the visu-
ospatial learning capabilities through the Barnes maze test.
We observed minor (not statistically different) changes in
latency to the first hole and more spatial preference for the
escape region (holes −1, 0, and 1) regardless of treatment
(data not shown). Taken together, these changes demonstrate
minor alterations in visuospatial memory suggesting that
simultaneous supplementation with Cu and Cho produces an
increment in exploratory activity—or a sort of overexcited
behavior—but with similar final results to those observed in
the other experimental groups.
4. Discussion
Supplementation of drinking water with low amounts of
inorganic Cu such as those used in our experiments was
able to modify the basal status of redox biomarkers not
only in peripheral plasma but also in the two zones of the
central nervous system explored, cortex and hippocampus.
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Figure 4: Calpains (𝜇- and m-) (U/min⋅mg total protein) activities
in brain cortex and hippocampus homogenates. Samples were
analyzed according to the procedures described in Section 2.11.2.
Treatments are indicated with different colors. Control (white bars),
Cu (gray bars), Cho (dark gray bars), and CuCho (black bars).
Results are expressed as mean of 6 rats assayed in triplicate ±
standard deviation (SD). Significant differences were indicated by
letters (data with distinct letters are statistically different between
them at 𝑃 < 0.01).
Because of their short life span, free radicals cannot be
measured directly, for which reason it is usual to analyze the
products arising from reactions caused by reactive species
with biomolecules. In line with this, we measured the end-
oxidation products of lipids (TBARS) and proteins (PCs) and
the production of NOx as biomarkers of prooxidative tissue
damage. PCs increased only after CuCho treatment; however,
TBARS and NOx increased after a sole exposure to trace
amounts of inorganic Cu in drinking water. The biomarkers
assayed were reproducible and sensitive to the experimental
stimuli. Many authors have associated neurodegenerative
illnesses with both a local (brain) and a systemic (plasma)
increase in oxidative stress [45–52]. Irrespective of whether
biomarkers are causative factors or whether they merely
constitute phenomenologically associated changes, they are
useful tools for evaluating the extent of damage and provide
a simple methodology for monitoring large populations
subjected to environmental Cu pollution or exposed to
other risks associated with the development of AD. There
is abundant evidence that transition metals in general, and
specially Cu, are causative factors for oxidative stress and,
as we mentioned previously, are strongly associated with the
neurodegenerative process [53–56].
The decrease of 𝛼-tocopherol in plasma and brain zones
homogenates and the increased GSSG/GSH ratio are both
markers of accumulation of reactive species in lipid- and
water-soluble cell compartments.The activation of GR can be
interpreted as a compensatory mechanism of the enzymatic
antioxidant defense system in order to normalize the altered
GSSG/GSH ratio induced by cotreatment with Cu and Cho.
In agreement with our results, Kojima et al. [57] have
demonstrated the induction of mRNA coding for GR in the
brain of mice irradiated with a low dose of 𝛾-rays. Also in
line with this, we can speculate that the observed increase in
plasma total glutathione levels may be due to a compensatory
mechanism under the oxidative insult evoked by the treat-
ment studied here. This explanation is in agreement with the
suggestions of other authors [58] andmay be the consequence
of an induction (overexpression) of cysteinyl-synthetase, the
enzyme that controls the biosynthesis of glutathione [59, 60].
The oxidative stress induced by NCBC could have multi-
ple effects on the signals cascade that depends on the redox
state and can alsomodify the activity of ionic channels, trans-
porters, and enzymes. Pallottini et al. [61] observed, in liver
of Wistar rats treated with thioacetamide, that HMGCoA-
reductase overactivation was strictly related to themagnitude
of the reactive species accumulated. Our results demonstrate
that inorganic Cu supplementation—even at the low levels
assayed—produced an increase in ECho levels in cortex and
hippocampus. Attributing the increase in Cho in brain to
oxidative stress-induced HMGCoA-reductase hyperactivity
could be oversimplistic, and this intriguing question remains
to be resolved on the basis of new experimental evidence.
Cho in the nervous system (10-fold higher than in any other
organ) is mainly unesterified [62, 63]. Furthermore, most of
the Cho content in brain depends on the in situ biosynthesis
that appears to be regulated by similar mechanisms both
outside and inside the brain, with HMGCoA-reductase being
the most important regulatory effector [63]. However, the
exact extent of Cho biosynthesis in neurons and astrocytes
in vivo remains unknown [62], making it difficult to esti-
mate the real effect of the accumulation of reactive species
(NCBC-induced) on brain Cho biosynthesis. Interestingly,
Cho turnover in individual neurons and astrocytes may in
fact be very high and reach an estimated 20% per day,
depending on the brain zone [62]. Unfortunately, the direct
effect of higher Cho levels in blood on Cho concentration
in brain is difficult to assess. Cho trafficking between brain
and peripheral blood implies the participation of the blood-
brain barrier (BBB) that hinders the direct passage into or
out of the central nervous system. However, for reasons not
yet understood, this restriction appears to be reduced in AD
and other neurodegenerative disorders [64]. Also, in certain
circumstances, for example, in cases of vascular injury due to
oxidative stress, the BBB could be permeable to interaction
with the peripheral pool of Cho [64].Moreover, recent exper-
imental evidence in a mouse model of AD demonstrated
that inflammation is one of the key factors in determining
increased BBB vulnerability [65]. Thus, from the above, we
can assume that peripheral Cho might cross the BBB into the
brain, in particular when the tissue is subjected to oxidative
stress and redox-induced inflammation as observed in our
experimental model.
Despite extensive research in recent years, the role of
Cho as a risk factor for AD remains controversial [64],
likely due to the still unresolved questions relating to the
exact role of peripheral Cho in its level in brain. We can
speculate that NCBC induces nitrative/oxidative and pro-
inflammatory conditions that probably facilitate endothelial
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damage and indirectly modify BBB properties [64, 65],
allowing peripheral Cho to enter the central nervous system.
Obviously, a great deal of experimental work is still required
to either confirm or refute this working hypothesis. Several
unresolved issues raise doubts concerning the beneficial
effects of statins in neurodegenerative patients and the notion
that high blood Cho is associated with brain dysfunction.
However, one possibility is that the real risk is the associ-
ation of hypercholesterolemia with a prooxidative and pro-
inflammatory environment induced, for example, by NCBC.
Brain Cho is involved in synaptogenesis, the turnover,
maintenance, stabilization, and restoration of synapses [63].
The functionality of synapses requires specific lipid domains
in neuronal and axon membranes whose composition is
critical for the correct targeting of the major membrane
proteins, myelin biogenesis, cellular differentiation, signal
transduction, and many other functions that depend on
microdomains and specific lipid rafts. The proportion of free
Cho to ECho in these membrane domains is a crucial factor
in their biological activities [63]. For example, the enzymes
responsible for the processing of the amyloid precursor
protein (APP) to A𝛽 (𝛽- and 𝛾-secretases) reside in Cho-rich
lipid rafts of plasma membrane [66]. It was suggested that a
higher total Cho/phospholipid ratio in cellular membranes
could affect secretase activities and determine preferential
APPprocessing pathways [66], though in vitro studies suggest
that Cho might impair the transcription of APP and con-
sequently decrease the availability for its conversion to 𝛽A.
However, it appears that this effect has no significant impact
on the amount of protein (that still exceeds the capacity of
the secretase system to process it) and only a slight impact
on the levels of the mRNA encoding APP protein [67].
To date, there are no findings elucidating the exact role of
ECho and how the ratio of free to esterified forms is able to
modify secretase activity and other process associated with
the amyloidogenic cascade [63]. Zana et al. [45] suggest that
different sources of oxidative stress, such as NCBC, could
trigger the amyloidogenic pathway, which may explain the
higher A𝛽 1-42/1-40 ratio we observed in the brain cortex of
Cu-treated rats and in the group receiving both treatments
(CuCho).
The question as to how Cho and Cu interact to lower
the production of 𝛽A and enhance oxidative stress and
inflammation is difficult to address. Experimental evidence
obtained in culture cells demonstrates that exposure of
macrophages to CuSO
4
, at a level equivalent to NCBC in
humans, induces SREBP-2 and consequently the expression
of cholesterogenic enzymes [68], thus tentatively providing
a new explanation for the apparently additive effect we
observed between Cu and Cho. However, we were unable to
find similar evidence in neuron or astrocyte cultures, or even
in experiments conducted on live animals to explore these
findings. There is yet another possibility: that the association
of the two supplements (Cu andCho)may affect the clearance
of 𝛽A and facilitate its accumulation. Working with rabbits
fed on a diet with excess Cho and inorganic Cu in their
drinking water, Sparks et al. [69] proposed that Cho caused
alterations in the BBB associated with an inflammatory con-
dition and a concomitant overproduction of 𝛽A in the brain.
In this model, Cu decreased the clearance of 𝛽A to the blood
via inhibition of LRP at the vascular interface [69]. Impaired
Cho metabolism, oxidative stress, and inflammation were all
factors associatedwith the decreased clearance of the𝛽Apep-
tide [63, 69]. In addition, Lu et al. [14] also demonstrated that
Cu exacerbates 𝛽A amyloid-induced neurotoxicity through a
TNF-mediated inflammatory pathway.
Though the exact mechanism(s) underlying all these
effects is still unknown, it is nevertheless widely accepted
that the AD pathological cascade is likely to be a 2-stage
event where deposition of 𝛽A and neuronal pathology (tauo-
pathy, neuronal injury, and programmed cell death, or
subsequent neurodegeneration with synapse and cognitive
loss) are sequential rather than simultaneous processes [70,
71]. Our model likely represents a very early step in these
successive events since the screening of the damages observed
in visuospatial memory revealed only slight modifications.
The Barnes maze test analysis demonstrated that all groups
display almost normal locomotor and exploratory activities
and spatial memory retention. The behavioral modifications
indicate that the animals of the control and Cho groups were
fully able to acquire the necessary knowledge for the spatial
task through training, whereas the Cu and CuCho groups
were only partially able to do so or presented slight learning
difficulties. Interestingly, these learning difficulties weremore
evident during the evaluation trials of Cho animals, which
explored holes very distant from the escape-hole region.
Nevertheless, Cho and CuCho animals both showed a minor
degree (not statistically significant) of deficit in learning and
spatial memory capabilities.
Plasma levels of 𝛽A, particularly the 𝛽A 1-40/𝛽A 1-42
ratio, are well-recognized biomarkers of sporadic AD [72, 73]
and even indicators of early stages of the pathology [74].
However, apart from its role as a biomarker, accumulation of
𝛽A peptide in brain is a complex phenomenon with multiple
and consecutive (sometimes unexpected) consequences [75].
In agreement with this, Tamagno et al. [76] demonstrated
that oxidative stress induced by A𝛽25–35 resulted in an
early, significant, and time-dependent generation of free
HNE (hydroxyl-nonenal) and H
2
O
2
. Also, other authors
reported increased levels of oxidative stress biomarkers after
A𝛽 exposure both in vivo and in vitro [77–79]. Our results are
therefore in agreement with those of other groups reporting
that oxidative stress and A𝛽 are linked to one another.
Apparently, A𝛽 can induce oxidative stress [80, 81], and pro-
oxidants such as NCBC can increase A𝛽 production [82–84]
in the manner of an autostimulated process.
The increased levels of the two main proinflamma-
tory prostaglandins (E2 and F2𝛼) are consistent with the
inflammatory condition characteristic of AD [85]. This pro-
inflammatory and prooxidative environment triggers the
activation of calpains, whereas caspase-3 activity was not sig-
nificantly stimulated under our experimental conditions. In
previous papers, we also found such dissociation between the
effects of inorganicCuoverload on the relative activities of the
two protease systems, which—at least in vitro experiments—
appear to depend on the extent and intensity of exposure to
Cu overload [86]. However, in view of previous experimental
evidence, we cannot conclude that neuronal death is actually
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occurring. So far, Saito et al. [87] have reported that the
activation of 𝜇-calpains in AD brain is not necessarily a
consequence of the endstage of neuronal degeneration and
may reflect a more widespread metabolic alteration that
precedes and contributes to neuronal death. In fact, they
observed increased activity of 𝜇-calpains in the cerebellum
of AD without any increase in the rate of death neurons [87].
In line with this, Nixon [88] established that different factors
could lead to calpain activation triggering neurodegeneration
in the early stages of AD development. Moreover, Trinchese
et al. [89] also reported that calpains have many substrates
that could be affected in AD patients but do not necessarily
lead to immediate cell death. They also stated that 𝜇-calpains
are present predominantly in synapses, which is in agreement
both with the fact that Cu concentration is particularly high
(micromolar) in the synaptic cleft [90] and with the well-
established synaptic pathology in AD [90, 91]. Nixon [88]
suggested that increased activity of calpains during normal
aging may also promote the development of neurological
disorders and impaired calcium homeostasis, both of which
could impact on the role of this cation in the function of
cellular membrane receptors and metallosignaling in brain
[91].
Finally, in discussing the validity and/or limitations of
our experimental system, it is necessary to consider the level
of the supplementation with Cu using oral administration.
Our experimental conditions were based on previous work
[13, 14] and resemble the Cu levels commonly found as a
consequence of involuntary exposure through air, food and
water pollution [16, 92–94], ingestion of dietary mineral sup-
plements, exposure of professionals engaged in agrochemical
activities [6, 11, 95], neurodegenerative patients and their
first-degree relatives, or female users of Cu-based intrauterine
devices [17, 19]. Studies performed in rats demonstrated that
Cu metabolism and homeostasis are essentially identical to
those in humans [96]. In terms of dosage, the rats from
the groups supplemented with Cu received 1.06 ± 0.11mg
Cu/Kg/day (including Cu acquire from food and water
ingestion). From the available data in humans, we can assume
that general population are receiving 0.16 to 0.98 EAR or
RDA which is equivalent to 0.3 to 1.5mg Cu/kg body weight
[97]. Very probably, humans are exposed to several types of
Cu-based compounds of different chemical structures with
differences in their physical stabilities, solubility, absorption
capacities, life’s times into the organism, and many other
particularities related to their excretion or bioaccumulation
rates. However, only inorganic Cu should be dangerous for
its probable role as causative factor for neurodegeneration
[3, 6, 8–10]. Thus, we think that there are a lot of questions
to be answered before drawing a realistic conclusion about
the comparisons between our experimental conditions and
the actual human expose to Cu.
5. Conclusions
In conclusion, this in vivo study reveals that the association
of inorganic Cu and Cho gives rise to a prooxidative and
proinflammatory environment more pronounced than that
produced by Cu and Cho administered alone. As described
before, the combination of these two factors is common in
many human populations. We suggest that the biochemical
changes observed, in particular, oxidative stress, inflamma-
tion, and the higher A𝛽 1-42/1-40 ratio in the cortex of
rats fed on Cu + Cho (CuCho), could constitute the initial
stages of the development of neurodegenerative disease. In
view of the abundant evidence of disturbed Cu homeostasis
in AD [7, 56, 98, 99], we strongly recommend more in-
depth studies on the mechanism(s) responsible for the pro-
neurodegenerative effect(s) of the association betweenNCBC
and Cho. Furthermore, it is recommended that the present
experimental evidence be used to promote the investigation
of the emerging biomarkers—such as those examined in this
work—to be applied in peripheral plasma as predictive tool(s)
in high-risk populations.
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